CD4 and neoplasm: found that selective deletion of Ezh2 in CD4+Treg delays tumor progression in mice, while the use of Ezh2 inhibitors in wild-type mice enhances the function of cytotoxic T lymphocytes (CTLs) and promotes the efficacy of anti-CTLA-4 antibodies, thus inhibiting tumor progression (33).